Autologous stem cell transplantation
In an autologous transplant, the patient's own blood-forming stem cells are collected and frozen before high-dose chemotherapy, then returned by infusion to rebuild the bone marrow. Because the cells are the patient's own, there is no rejection and no graft-versus-host disease, although a small risk remains that cancer cells are returned together with the graft. It is a standard consolidation treatment in multiple myeloma and is also used in some lymphomas and in selected childhood solid tumors such as neuroblastoma.
How it works
Used in
Consolidation after methotrexate-based induction in younger, fit patients — an alternative to whole-brain radiotherapy with its late neurotoxicity.
Relapsed or refractory Hodgkin lymphoma after effective salvage chemotherapy — undertaken with curative intent.
Relapsed chemosensitive diffuse large B-cell lymphoma; in early relapse CAR-T therapy has displaced it for a subset of indications.
High-dose melphalan consolidation with autologous rescue in transplant-eligible myeloma patients — part of standard first-line treatment.
High-dose chemotherapy with autologous rescue in salvage treatment of relapsed germ cell tumours after failure of standard therapy.